Williams, Ken

Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance

DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 766

Does the Metabolic Syndrome Improve Identification of Individuals at Risk of Type 2 Diabetes and/or Cardiovascular Disease?

Stern, M. P., Williams, K., González-Villalpando, C., Hunt, K. J., & Haffner, S. M. (2004) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 735

National Cholesterol Education Program Versus World Health Organization Metabolic Syndrome in Relation to All-Cause and Cardiovascular Mortality in the San Antonio Heart Study

Hunt, K. J., Resendez, R. G., Williams, K., Haffner, S. M., & Stern, M. P. (2004) · Circulation

Diabetes, Cardiovascular Risks, and LipoproteinsCardiovascular Health and Risk Factors

Cited by 662

A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk

Sniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011) · Circulation: Cardiovascular Quality and Outcomes

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 659

Fueling the obesity epidemic? Artificially sweetened beverage use and long-term weight gain.

Fowler, S. P., Williams, K., Resendez, R. G., Hunt, K. J., Hazuda, H. P., & Stern, M. P. (2008) · Obesity

Biochemical Analysis and Sensing TechniquesObesity, Physical Activity, Diet

Cited by 464

Identification of Individuals With Insulin Resistance Using Routine Clinical Measurements

Stern, S. E., Williams, K., Ferrannini, E., DeFronzo, R. A., Bogardus, C., & Stern, M. P. (2005) · Diabetes

Diabetes, Cardiovascular Risks, and LipoproteinsAdipokines, Inflammation, and Metabolic Diseases

Cited by 384

What is the best predictor of future type 2 diabetes

Abdul-Ghani, M. A., Williams, K., DeFronzo, R. A., & Stern, M. (2007) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsPancreatic function and diabetes

Cited by 355

Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C

Pencina, M. J., D’Agostino, R. B., Zdrojewski, T., Williams, K., Thanassoulis, G., Furberg, C. D., Peterson, E. D., Vasan, R. S., & Sniderman, A. D. (2015) · European Journal of Preventive Cardiology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 164

Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials

Thanassoulis, G., Williams, K., Ye, K., Brook, R., Couture, P., Lawler, P. R., de Graaf, J., Furberg, C. D., & Sniderman, A. (2014) · Journal of the American Heart Association

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 148